2m 2m 2m 2m 2m 2m 2m
TARSUS PHARMA (TARS)
NASDAQ
$66.21+$2.65 (+4.17%)
Price as of Jun 23, 2026 5:03 PM EDT- $2.7BMarket Cap
- 56.55%1-Year Change
- BiotechnologyIndustry
TARSUS PHARMA (TARS)
$66.21+$2.65 (+4.17%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 451.4M +146.71% | 183.0M +948.62% | 17.4M -32.42% | 25.8M -54.73% | |
Cost of Revenue | 30.7M +19.62% | 25.7M +1,510.30% | 1.6M +66.81% | 955,000 -53.98% | |
Gross Profit | 420.7M +167.43% | 157.3M +892.18% | 15.9M -36.23% | 24.9M -54.76% | |
Sales and Marketing Expense | 427.3M +80.07% | 237.3M +118.32% | 108.7M N/A | N/A N/A | |
Research and Development Expense | -64.3M +20.48% | -53.4M +6.11% | -50.3M +18.04% | -42.6M +2.19% | |
Depreciation and Amortization Expense | 961,000 +77.96% | 540,000 +306.02% | 133,000 -59.08% | 325,000 +4.17% | |
Total Operating Expenses | 522.3M +72.09% | 303.5M +88.99% | 160.6M +81.42% | 88.5M +27.96% | |
Operating Profit | -71.0M -41.14% | -120.6M -15.78% | -143.2M +128.28% | -62.7M +415.85% | |
Interest Income | 15.7M +4.88% | 15.0M N/A | N/A N/A | N/A N/A | |
Interest Expense | -8.9M +13.84% | -7.8M +134.58% | -3.3M +52.16% | -2.2M N/A | |
Interest Income and Expense and Net | 6.8M -4.93% | 7.2M +314.14% | -3.3M +52.16% | -2.2M N/A | |
Total Nonoperating Income and Expense | 6.6M +31.80% | 5.0M -30.97% | 7.3M +1,077.47% | 617,000 +138.20% | |
Income before Taxes | -64.4M -44.30% | -115.6M -14.97% | -135.9M +118.85% | -62.1M +350.88% | |
Income Taxes | 2.1M N/A | 0 N/A | 0 +100.00% | -4,000 -107.27% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -66.4M -42.52% | -115.6M -14.97% | -135.9M +118.86% | -62.1M +349.06% | |
Net Income from Continuing Operations Applicable to Common | -64.4M -44.30% | -115.6M -14.97% | -135.9M +118.85% | -62.1M +350.88% | |
Basic EPS and Net Income | -1.59 -48.21% | -3.07 -33.55% | -4.62 +83.33% | -2.52 +276.12% | |
Diluted EPS and Net Income | -1.59 -48.21% | -3.07 -33.55% | -4.62 +83.33% | -2.52 +276.12% | |
Basic Weighted Average Shares | 41.8M +11.11% | 37.6M +27.98% | 29.4M +19.35% | 24.6M +19.78% | |
Diluted Weighted Average Shares | 41.8M +11.11% | 37.6M +27.98% | 29.4M +19.35% | 24.6M +19.78% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 183.6M +93.68% | 94.8M -57.85% | 224.9M +213.91% | 71.7M -58.17% | |
Short-Term Investments | 233.6M +18.86% | 196.6M +7,778.04% | 2.5M -98.28% | 145.4M +29,996.48% | |
Cash and Cash Equivalents and Short-Term Investments | 417.3M +43.21% | 291.4M +28.11% | 227.4M +4.80% | 217.0M +26.31% | |
Total Current Assets | 522.8M +46.56% | 356.7M +39.27% | 256.1M +13.65% | 225.4M +28.09% | |
Accumulated Depreciation | 2.1M +6.17% | 2.0M +53.18% | 1.3M +136.26% | 546,000 +147.06% | |
Property and Plant and Equipment and Net | 11.7M +404.11% | 2.3M +57.63% | 1.5M +53.40% | 957,000 +26.75% | |
Total Long-Term Assets | 1.9M +86.29% | 999,000 -34.02% | 1.5M +158.80% | 585,000 -48.05% | |
Total Assets | 562.2M +49.12% | 377.0M +42.00% | 265.5M +16.51% | 227.9M +27.36% | |
Income Taxes Payable | 1.8M N/A | N/A N/A | N/A N/A | 14,000 -74.55% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 135.7M +68.33% | 80.6M +118.25% | 36.9M +139.39% | 15.4M +34.42% | |
Total Long-Term Debt | 72.4M +0.83% | 71.8M +140.94% | 29.8M +53.44% | 19.4M N/A | |
Total Long-Term Liabilities | 10.6M N/A | 0 -100.00% | 1.7M +1,648.00% | 100,000 -85.69% | |
Total Liabilities | 218.7M +43.47% | 152.5M +122.56% | 68.5M +95.93% | 35.0M +187.12% | |
Retained Earnings | -426.6M +18.44% | -360.2M +47.23% | -244.7M +124.94% | -108.8M +133.04% | |
Total Stockholders Equity | 343.4M +52.95% | 224.5M +13.98% | 197.0M +2.12% | 192.9M +15.70% | |
Total Shares Outstanding | 42.6M +10.96% | 38.3M +12.10% | 34.2M +28.00% | 26.7M +29.13% | |
Cash Flow | |||||
Cash from Operating Activities | -12.5M -85.00% | -83.0M -29.33% | -117.5M +139.63% | -49.0M -1,408.16% | |
Capital Expenditures | 9.9M +529.16% | 1.6M +4.33% | 1.5M +196.84% | 506,000 -13.65% | |
Cash from Investing Activities | -42.1M -78.86% | -199.2M -241.67% | 140.6M +197.22% | -144.6M +24,580.72% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 143.4M -7.29% | 154.7M +18.81% | 130.2M +38.50% | 94.0M +447,457.14% | |
Financials Ratio | |||||
Gross Margin | 93.20% +8.40% | 85.98% -5.38% | 90.87% -5.64% | 96.30% -0.06% | |
Operating Margin | -15.72% -76.14% | -65.90% -91.97% | -820.53% +237.78% | -242.92% +1,039.50% | |
Return on Assets | -14.14% -60.68% | -35.97% -34.70% | -55.09% +80.45% | -30.53% +287.36% | |
Return on Equity | -23.39% -57.34% | -54.83% -21.35% | -69.71% +101.88% | -34.53% +315.44% | |
Revenue Growth | 146.71% -84.53% | 948.62% +3,026.23% | -32.42% -40.77% | -54.73% N/A | |
Current Ratio | 3.85 -12.94% | 4.43 -36.19% | 6.93 -52.53% | 14.61 -4.71% | |
Cash Ratio | 1.35 +15.06% | 1.18 -80.69% | 6.09 +31.13% | 4.64 -68.89% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow